Developing complex biologics and advanced therapies is historically time-consuming and material-intensive—but computational modeling is reshaping the formulation landscape.

In this episode of Life Science Solutions, host Chris Adkins is joined by Andrea Arsiccio, PhD, Senior Scientist and Team Lead In Silico at Coriolis Pharma, to discuss how in silico modeling is revolutionizing the assessment of developability and formulation strategies for new drug products.

Andrea breaks down how Coriolis Pharma combines physics-based models and Artificial Intelligence with traditional wet lab experimentation to predict molecule behavior, identify liabilities early, and solve complex problems like aggregation and viscosity.

Topics Include:

• Defining In Silico: Understanding the spectrum from mechanistic models and molecular dynamics to AI and machine learning.
• Accelerating Development: How computational tools reduce the need for animal testing and save precious material in early-phase development.
• The "Why" Behind the "What": Using modeling to uncover the specific mechanisms causing instability or aggregation.
• The Hybrid Approach: Validating digital predictions with high-throughput wet lab screening for a robust formulation strategy.
• Regulatory Perspectives: How the FDA and EMA are viewing AI data and the importance of establishing model credibility.
• Expansion: Coriolis Pharma’s growth into the US market and their new capabilities in Research Triangle Park.

Whether you are a formulation scientist, a CMC leader, or a regulatory professional, this episode provides a fascinating look at how digital twins and computational strategies are de-risking the path to market for life-saving therapies.

📍Recorded at Kymanox HQ in Research Triangle Park, North Carolina.

#Biologics #InSilico #DrugDevelopment #FormulationScience #AIinPharma #CoriolisPharma #LifeSciences #Kymanox